Vigeo Therapeutics, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Cambridge MA United States (2011)

Organization Overview

First Clinical Trial
2017
NCT03364400
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Senior Medical Director | Vigeo Therapeutics, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 8